Protein-tyrosine phosphatase H1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at Tyr537

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 230-238

  Suresh, Padmanaban S ^a,d   Ma, Shao ^a   Migliaccio, Antimo ^c   Chen, Guan ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d VIT UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 3; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BREAST CANCER; CATALYSIS; CELL FRACTIONATION; CELL STRAIN MCF 7; COLONY FORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG SENSITIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 3; TAMOXIFEN; TYROSINE;

EID: 84892585177     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0610     Document Type: Article

References (38)

1. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276: 36869-72.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
3. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25: 5815-24.
4. de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011;2011:232435.
5. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
6. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RE, Egly J, et al. Activation of estrogen receptor a by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 2000;6:127-37.
7. Qi X, Zhi H, Lepp A, Wang P, Huang J, Basir Z, et al. p38g mitogenactivated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. J Biol Chem 2012;287:14681-91.
8. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S, et al. Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 2009;101:1725-9.
9. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang R, et al. p21-activated kinase 1 regulation of estrogen receptor-α activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006;66:1694-701.
10. Bostner J, Skoog L, Formander T, Nordenskjold B, Stal O. Estrogen receptor-α phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010;16:1624-33.
11. Arnold SF, Vorojeikina DP, Notides AC. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 1995;270:30205-12.
12. Arnold S, Notides AC. An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. Proc Natl Acad Sci U S A 1995;92:7475-9.
13. Castoria G, Giovannelli P, Lombardi M, Rosa CD, Giraldi T, Falco A, et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012;31:4868-77.
14. Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol 2012;26:1567-77.
15. Skliris GP, Nugent Z, Watson PH, Murphy LC. Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen. Horm Canc 2010;1:215-21.
16. Zhang Q, Borg A, Wolf DM, Oesterreich S, Fuqua SAW. An estrogen receptor mutuant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244-9.
17. Arnold SF, Oburn JD, Jaffe H, Notides AC. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by Src family tyrosine kinases. Mol Endocrinol 1995;9:24-33.
18. Yang Q, Tonks NK. Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase withhomology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin. Proc Natl Acad Sci U S A 1991;88:5949-53.
19. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J Ptak, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-6.
20. Hou SW, Zhi H, Pohl N, Loesch M, Qi X, Li R, et al. PTPH1 dephosphorylates and cooperates with p38γ MAPK to increases Ras oncogenesis through PDZ-mediated interaction. Cancer Res 2010;70: 2901-10.
21. Hou S, Padmanaban S, Qi X, Leep A, Mirza S, Chen G. p38γ MAPK signals through phosphorylating its phosphatase PTPH1 in regulating Ras oncogenesis and stress response. J Biol Chem 2012;287: 27895-905.
22. Zhi H, Hou S, Li R, Basir Z, Xiang Q, Szabo A, et al. PTPH1 cooperates with vitamin Dreceptor to stimulate breast cancer growth through their mutual stabilization. Oncogene 2011;30:1706-15
23. Zhang S-H, Liu J, Kabayashi R, Tonks NK. Identification of the cell cycle regulator VCP (p97/CDC48) as a substrate of the band 4.1- related protein-tyrosine phosphatase PTPH1. J Biol Chem 1999;274: 17806-12.
24. Qi X, Hou S, Lepp A, Li R, Basir Z, Lou Z, et al. Phosphorylation and stabilization of topoisomerase IIα by p38γ MAPK sensitize breast cancer cells to its poisons. J Biol Chem 2011;286:35883-90.
25. Deol Y, Nasser MW, Yu L, Zou X, Ganju RK. Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells. J Biol Chem 286:44845-54.
26. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33.
27. Chen G, Baechle A, Nevins TD, Oh S, Harmon C, Stacey WD. Protection against cyclophosphamide-induced alopecia and inhibition of mammary tumor growth by topical 1,25-dihydroxyvitamin D3 in mice. Int J Cancer 1998;75:303-9.
28. Lymperatou D, Giannopoulou E, Koutras AK, Kalofonos HP. The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently. Bio Med Res Internat 2013;2013:147514.
29. Harvell DME, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinol 2006;147:700-13.
30. Lee EJ, Jakacka M, Duan WR, Chien PY, Martinson F, Gehm BD, et al. Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. Mol Med 2001;7:773-82.
31. Fan P, Wang J, Santen RJ, Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007;67:1352-60.
32. Jakesz R, Altken CA, Aitken S, Huff K, Schuette W, Shackney S, et al. Influence of cell proliferation and cell-cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1984;44: 619-25.
33. Xu Y, Tan L, Grachtchouk V, Voorhees JJ, Fisher GJ. Receptor-type protein-tyrosine phosphatase-α regulates epidermal growth factor receptor function. J Biol Chem 2005;280:42694-700.
34. He X, Zheng Z, Song T, Wei C, Ma H, Zhang Y, et al. c-Abl regulates estrogen receptor a transcription activity through its stabilization by phosphorylation. Oncogene 2010;29:2238-51.
35. Varricchio L, Migliaccio A, Castoria G, Yamaguchi H, de Falco A, Di Domenico M, et al. Inhibition of estradiol receptor/Src association and cell growth by an estradio receptor a tyrosine-phosphorylated peptide. Mol Cancer Res 1997;5:1213-21.
36. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, et al. Protein phosphatase 2A regulates estrogen receptor α (ER) expression through modulation of ER mRNA stability. J Biol Chem 2005;280: 29519-24.
37. Sekine Y, Ikeda O, Hayakawa Y, Tsuji S, Imoto S, Aoki N, et al. DUSP22/LMW-DSP2 regulates estrogen receptor-α-mediated signaling through dephosphorylation of Ser-118. Oncogene 2007;26: 6038-49.
38. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38γ MAPK integrates signaling cross-talk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006;66:7540-7.